Ipilimumab/nivolumabGrade 3 autoimmune hepatitis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1929卷 / 1期

关键词：

D O I：

10.1007/s40278-022-25983-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：359 / 359

相关论文

共 50 条

[31] PhenytoinFirst report of autoimmune hepatitis: case report
[J]. Reactions Weekly, 2012, 1429 (1) : 33 - 33
[32] RamelteonFirst report of autoimmune hepatitis: case report
[J]. Reactions Weekly, 2013, 1466 (1) : 38 - 38
[33] MeloxicamFirst report of autoimmune hepatitis: case report
[J]. Reactions Weekly, 2010, 1301 (1) : 34 - 34
[34] EfalizumabFirst report of autoimmune hepatitis: case report
[J]. Reactions Weekly, 2010, 1297 (1) : 23 - 23
[35] OrnidazoleFirst report of autoimmune hepatitis: case report
[J]. Reactions Weekly, 2001, 864 (1) : 10 - 10
[36] RosuvastatinFirst report of autoimmune hepatitis: case report
[J]. Reactions Weekly, 2005, 1053 (1) : 17 - 17
[37] MelatoninFirst report of autoimmune hepatitis: case report
[J]. Reactions Weekly, 1997, 668 (1) : 9 - 9
[38] Ipilimumab/nivolumabMyasthenia gravis, hepatitis and thyroiditis: case report
[J]. Reactions Weekly, 2020, 1810 (1) : 122 - 122
[39] Ipilimumab/prednisoneAutoimmune colitis and cytomegalovirus hepatitis: case report
[J]. Reactions Weekly, 2015, 1557 (1) : 131 - 131
[40] Ipilimumab/nivolumabImmune-related hepatitis: case report
[J]. Reactions Weekly, 2020, 1792 (1) : 134 - 134

← 1 2 3 4 5 →